Ripretinib

What is Ripretinib?[edit | edit source]

Ripretinib (Qinlock) is a kinase inhibitor used to treat adults with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior treatments for their GIST.

This medicine is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, and secondary mutations.
Ripretinib also inhibits other kinases in vitro, such as PDGFRB, TIE2, VEGFR2, and BRAF.
Upon oral administration, ripretinib targets and binds to both wild-type and mutant forms of KIT and PDGFRa specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms.
This abrogates KIT/PDGFRa-mediated tumor cell signaling and prevents proliferation in KIT/PDGFRa-driven cancers.
DCC-2618 also inhibits several other kinases, including vascular endothelial growth factor receptor type 2 (VEGFR2; KDR), angiopoietin-1 receptor (TIE2; TEK), PDGFR-beta and macrophage colony-stimulating factor 1 receptor (FMS; CSF1R), thereby further inhibiting tumor cell growth.
KIT and PDGFRa are tyrosine kinase receptors that are upregulated or mutated in a variety of cancer cell types; mutated forms play a key role in the regulation of tumor cell proliferation and resistance to chemotherapy.

Avoid Coadministration of Qinlock with fallowing:

The recommended dosage of Qinlock is 150 mg orally once daily with or without food until disease progression or unacceptable toxicity.

Administration

Take Qinlock exactly as your healthcare provider tells you to.
Your healthcare provider may temporarily or permanently stop treatment or change your dose of Qinlock if you develop side effects during treatment.
Do not change your dose or stop taking Qinlock unless your healthcare provider tells you to.
Take Qinlock 1 time each day, at the same time each day.
Take Qinlock with or without food.
Swallow Qinlock tablets whole.
If you vomit after taking a dose of Qinlock, do not take an extra dose. Take your next dose of Qinlock at your scheduled time.
If you miss a dose of Qinlock, take it as soon as you remember if it is within 8 hours of the scheduled dose. If more than 8 hours have passed, wait until your next scheduled dose.
If you take more than the prescribed dose of Qinlock, call your healthcare provider.

This medicine is available in fallowing doasage form:

This medicine is available in fallowing brand namesː

Common possible side effects of this medicine include: Common possible side effects of this medicine include:

Qinlock may cause serious side effects, including:

Qinlock may cause serious side effects, including:

Palmar-Plantar Erythrodysesthesia Syndrome may occur. Based on severity, withhold Qinlock and resume at same or reduced dose.
Perform dermatologic evaluations when initiating Qinlock and routinely during treatment.
Do not initiate Qinlock in patients with uncontrolled hypertension and monitor blood pressure during treatment. Based on severity, withhold Qinlock and then resume at same or reduced dose or permanently discontinue.
Permanently discontinue Qinlock for Grade 3 or 4 left ventricular systolic dysfunction.
This medicine increases the risk of impaired wound healing. Withhold Qinlock for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks after major surgery and until adequate wound healing.
Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

Overdose related information is also available online at poisonhelp.org/help.
In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

Qinlock can cause fetal harm when administered to a pregnant woman.
There are no available data on the use of Qinlock in pregnant women to inform a drug-associated risk.

The safety and effectiveness of Qinlock in pediatric patients have not been established.

Store in the original container with the desiccant to protect from moisture and light. Replace cap securely each time after opening. Do not discard desiccant.
Store at 20°C to 25°C (68°F to 77°F); excursion permitted between 15°C to 30°C (59°F to 86°F)

Ripretinib Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski

Need help finding a doctor or specialist anywhere in the world? WikiMD's DocFinder can help with millions of doctors!

This article is a stub. Help WikiMD grow by registering to expand it. Editing is available only to registered and verified users. About WikiMD: A comprehensive, free health & wellness encyclopedia.

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.